A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% ...

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 12.3% in the afternoon session after the company reported better-than-expected first-quarter 2026 results.

Novavax on Wednesday beat Wall Street estimates for first-quarter revenue, as milestone payments from vaccine ​supply and ...

Novavax delivered first quarter results that surpassed Wall Street’s revenue and earnings estimates, leading to a significant ...

The outbreak of Hantavirus on a cruise ship has led to biotech and pharmaceutical stocks surging on reports of firms ...

(Reuters) -Novavax shares jumped more than 15% on Monday after the company secured a long-awaited U.S. regulatory approval for its COVID-19 vaccine, albeit with new conditions, which helped allay some ...

Novavax posted Q1 revenue of $139.5 million, above analysts’ estimate of $78.3 million, helped by licensing agreements. ・The drugmaker also said that patients who received Nuvaxovid were “twice as ...

In the latest close session, Novavax (NVAX) was up +1.01% at $8.01. The stock outperformed the S&P 500, which registered a daily gain of 0.29%. Elsewhere, the Dow lost 0.31%, while the tech-heavy ...

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close ...

Add Yahoo as a preferred source to see more of our stories on Google. Food and Drug Administration commissioner Martin Markary speaks during an event in the Roosevelt Room at the White House, Monday, ...